Astellas Pharma buys Iveric Bio for $5.9 bln

IVERIC bio

01/05/2023 24:12

May 1 (Reuters) - Japan's Astellas Pharma  4503.T  said
on Monday it had fully acquired drugmaker IVERIC Bio Inc
 ISEE.N , through Berry Merger Sub, Inc, a wholly-owned
subsidiary of Astellas US Holding, Inc.
    Astellas bought IVERIC for $40.00 per share in cash, for a
total equity value of approximately $5.9 billion.

 (Reporting by Baranjot Kaur in Bengaluru; Editing by Kim
Coghill)
 ((Baranjot.Kaur@thomsonreuters.com; +91 86990 46242;))